Last reviewed · How we verify

TAK-279

Takeda · Phase 3 active Small molecule Under review

TAK-279 is a SGLT2 inhibitor Small molecule drug developed by Takeda. It is currently in Phase 3 development for Treatment of type 2 diabetes. Also known as: Zasocitinib.

TAK-279 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).

TAK-279 is a small molecule RAF serine/threonine protein kinase inhibitor, classified as an inhibitor. It is being studied in clinical trials for conditions such as ulcerative colitis and psoriatic arthritis, and is being compared to a placebo and the drug Zasocitinib.

Likelihood of approval
61.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
  • Big-pharma sponsor +3.0pp
    Takeda is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030 —
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameTAK-279
Also known asZasocitinib
SponsorTakeda
Drug classSGLT2 inhibitor
TargetSGLT2
ModalitySmall molecule
Therapeutic areaDiabetes
PhasePhase 3

Mechanism of action

By inhibiting SGLT2, TAK-279 reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and decreased glucose levels in the blood. This mechanism is thought to contribute to its therapeutic effects in treating type 2 diabetes.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about TAK-279

What is TAK-279?

TAK-279 is a SGLT2 inhibitor drug developed by Takeda, indicated for Treatment of type 2 diabetes.

How does TAK-279 work?

TAK-279 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).

What is TAK-279 used for?

TAK-279 is indicated for Treatment of type 2 diabetes.

Who makes TAK-279?

TAK-279 is developed by Takeda (see full Takeda pipeline at /company/takeda).

Is TAK-279 also known as anything else?

TAK-279 is also known as Zasocitinib.

What drug class is TAK-279 in?

TAK-279 belongs to the SGLT2 inhibitor class. See all SGLT2 inhibitor drugs at /class/sglt2-inhibitor.

What development phase is TAK-279 in?

TAK-279 is in Phase 3.

What are the side effects of TAK-279?

Common side effects of TAK-279 include Increased risk of genital mycotic infections, Increased risk of urinary tract infections, Hypotension, Nausea, Diarrhea.

What does TAK-279 target?

TAK-279 targets SGLT2 and is a SGLT2 inhibitor.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing